Finally, a clinical trial of CC-930 (the pan-JNK inhibitor used in our study) in patients with idiopathic pulmonary fibrosis (NCT01203943) was terminated due to an unfavorable benefit/risk profile. This evidence concerns the gene MAPK8 and pulmonary fibrosis.